Formation of specialized pro-resolving lipid mediators (SPMs) such as lipoxins or resolvins
usually involves arachidonic acid 5-lipoxygenase (5-LO, ALOX5) and different types of …

First isolated from Cannabis in 1940 by Roger Adams, the structure of CBD was not
completely elucidated until 1963. Subsequent studies resulted in the pronouncement that …

Recent insights into the pathophysiologic underlying mechanisms of obesity have led to the
discovery of several promising drug targets and novel therapeutic strategies to address the …

Cannabidiol (CBD) is a major phytocannabinoid present in Cannabis sativa (Linneo, 1753).
This naturally occurring secondary metabolite does not induce intoxication or exhibit the …

Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964,
when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic …

Systemic scleroderma (SSc) is one of the most complex systemic autoimmune diseases. It
targets the vasculature, connective tissue-producing cells (namely fibroblasts/myofibroblasts …

There are at least two types of cannabinoid receptors (CB1 and CB2). Ligands activating
these G protein-coupled receptors (GPCRs) include the phytocannabinoid Δ9 …

Alzheimer's disease (AD) is a debilitating neurodegenerative disease that is affecting an
increasing number of people. It is characterized by the accumulation of amyloid-β and tau …

Cannabis sativa, commonly known as marijuana, contains a pool of secondary plant
metabolites with therapeutic effects. Besides Δ9-tetrahydrocannabinol that is the principal …

In 2005, the International Union of Basic and Clinical Pharmacology Committee on Receptor
Nomenclature and Drug Classification (NC-IUPHAR) published a catalog of all of the human …